The Conversation (0)
(TheNewswire)
 | |||||||||
 |  |  |  | ||||||
Calgary, Alberta TheNewswire - February 24, 2026 - Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSXV: OTC,OTC:OTCFF) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Raymond Marks has been appointed to its Board of Directors.
Raymond Marks was instrumental in the early fundraising efforts of the Company and participated in meetings that resulted in Ocumetics securing financing for its initial public listing by reverse takeover.
He has over 50 years of experience as an entrepreneur, owner, operator and manager across a variety of industries including the resources and industrial sectors. Throughout his career, Mr. Marks has worked with many such companies and has worked with growing companies to secure millions in financing for their strategic initiatives.
Mr. Marks previously co-founded Tudor Gold Corp. (TSXV:TUD) and served as executive Vice President, and a director of Tudor from February 2016 until October 2018. Mr. Marks later assisted in the formation of Hanstone Capital Corporation which later became Hanstone Gold Corp. where he served as President and Chief Executive Officer from October 2018 until October 2025. Mr. Marks helped secure over $16 million in financing for the two companies.
"We welcome Mr. Marks to the board of Ocumetics and look forward to benefiting from his capital markets experience and assistance with our next stage of fundraising," says Dean Burns, President and CEO of Ocumetics.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC,OTC:OTCFF) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.
Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Company. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Copyright (c) 2026 TheNewswire - All rights reserved.
